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Abstract 1 
Background: Cartilage turnover and load-induced tissue changes are frequently assessed by 2 
quantifying concentrations of cartilage biomarkers in serum. To date information on the 3 
effects of ultramarathon running on articular cartilage is scarce. 4 
Hypothesis: Serum concentrations of cartilage oligomeric matrix protein (COMP), matrix 5 
metalloproteinases (MMP)-1, 3, and 9, collagen COL2−3/4Clong mono (C2C), collagen II C-6 
propeptide (CPII) and C2C:CPII will increase throughout a multistage ultramarathon. 7 
Study Design: Cross-sectional study. 8 
Methods: Five blood samples were collected from 38 runners (4 female; age, 49.0 ± 10.7 9 
years; body mass index, start: 23.1 ± 2.3 kg/m2, finish: 21.4 ± 1.9 kg/m2) before (t0) and 10 
during (t1: 1002 km; t2: 2132 km; t3: 3234 km; t4: 4039 km) a 4486 km multistage 11 
ultramarathon. Serum COMP, MMP-1, 3, and 9, C2C and CPII levels were assessed using 12 
commercial enzyme-linked immunosorbent assay. Linear mixed models were used to detect 13 
significant changes in serum biomarker levels over time with time-varying covariates body 14 
mass, running speed, and daily running time. 15 
Results: Serum concentrations of COMP, MMP-9 and MMP-3 changed significantly 16 
throughout the multistage ultramarathon. On average, concentrations increased during the 17 
first measurement interval (MI1: t1-t0) by 22.5% (change MI1 [95% confidence interval], 18 
COMP: [0.29;0.71] ng/mL), 22.3% (MMP-3: [0.24;15.37] ng/mL), and 95.6% (MMP-9: 19 
[81.7;414.5] ng/mL), and remained stable throughout MI2, MI3 and MI4. Serum 20 
concentrations of MMP-1, C2C, CPII, and C2C:CPII did not change significantly throughout 21 
the multistage ultramarathon. Changes in MMP-3 were statistically associated with changes 22 
in COMP throughout the ultramarathon race (MMP-3: Wald Z=3.476, P=.001). 23 
 3 
Conclusions: Elevated COMP levels indicate increased COMP turnover in response to 24 
extreme running, and the association between load-induced changes in MMP-3 and changes 25 
in COMP suggests the possibility that MMP-3 may be involved in the degradation of COMP. 26 
Clinical Relevance: These results suggest that articular cartilage is able to adapt even to 27 
extreme physical activity possibly explaining why the risk of degenerative joint disease is not 28 
elevated in the running population. 29 
Key Terms: Cartilage biomarkers, articular cartilage, tissue metabolism, extreme running 30 
What is known about the subject: The effect of extreme running on articular cartilage 31 
metabolism is poorly understood. 32 
What this study adds to the existing knowledge: Compared to single stage ultramarathons, 33 
COMP levels leveled off during the multistage ultramarathon suggesting that regular short 34 
recovery periods throughout ultra exercises in highly adapted ultra-endurance athletes may be 35 
sufficient for reaching a steady-state. Although the regulation of COMP is poorly understood, 36 
the statistical association between load-induced changes in MMP-3 and load-induced changes 37 
in COMP suggest that MMP-3 may be involved in the degradation of COMP. 38 
 4 
Introduction 1 
While in recent years, marathon running has become increasingly popular with more 2 
than 700 races per year worldwide and up to 50,000 participants per event34, single stage 3 
ultramarathons (distances >42 km without break) and multistage ultramarathons (distances 4 
>42 km per day over multiple days) are performed by fewer athletes per event with races of 5 
varying distances. Ultramarathons represent extreme stress for the human body not only 6 
because of the duration of the physical activity but also due to environmental conditions such 7 
as weather and terrain. 8 
The effects of multistage ultramarathon on health have received scientific interest, 9 
although the literature is largely limited to effects on the cardiovascular system18, 10 
respiratory43 and skeletal muscle38, and the gastrointestinal system38. Interestingly, to date 11 
information on the effects of ultramarathon running on articular cartilage is scarce. A 12 
previous study37 on a transcontinental multistage footrace over 4486 km reported an initial 13 
T2*-signal increase during the first 1000 km followed by a slight decrease throughout the 14 
remainder of the race (with medium to high effect sizes) without any morphological or 15 
cartilage thickness changes in the ankle joints. These changes were interpreted as an increase 16 
in glucosaminoglycan as observed by Roos and Dahlberg31 in the weight-bearing posterior 17 
medial femoral condyle following moderate exercise. While these results provide an 18 
indication for the ability of the normal cartilage matrix to partially regenerate under ongoing 19 
multistage ultramarathon burden in the ankle joints37, detailed knowledge on cartilage 20 
metabolism in response to extreme running exercise—especially with intermittent brief 21 
recovery periods such as during a multistage ultramarathon—is not available. 22 
Cartilage turnover and load-induced tissue changes are frequently assessed by 23 
quantifying concentrations of cartilage biomarkers in serum. Potential cartilage biomarkers 24 
include structural proteins or enzymes reflecting cartilage metabolism. For instance, elevated 25 
 5 
levels of cartilage oligomeric matrix protein (COMP) are associated with a higher incidence 26 
risk of knee osteoarthritis (OA)33, and load-induced changes in serum COMP predict 27 
cartilage thickness changes in patients with knee OA.6 COMP levels are sensitive to exercise 28 
bouts of walking (30 minutes20; 4000 steps5) and running (30 minutes25, 26; marathon (42 29 
km)22) but not to deep knee bends (120 in 30 minutes25). Previous studies have shown that 30 
COMP levels continue to increase throughout ultramarathon running races14, 38 in runners 31 
without osteoarthritis. Hence, load-induced changes in COMP appear to be sensitive to load 32 
magnitude and number of loading cycles during exercise bouts. 33 
Matrix metalloproteinases (MMPs) are a multi-member family of proteinases with a 34 
wide range of substrates including extracellular components, cytokines, receptors, and cell 35 
motility factors.19, 44 For instance, interstitial collagenase (MMP-1) is produced by 36 
chondrocytes, osteoblasts and synovial cells that degrades collagen types I, II, and III in the 37 
extracellular matrix and mediates cartilage destruction2, 40, and is expressed at higher levels 38 
by OA chondrocytes than by normal chondrocytes suggesting a predominant role of MMP-1 39 
in OA pathogenesis.7, 39 Stromelysin-1 (MMP-3) is in part responsible for the degradation of 40 
non-collagen matrix proteins in cartilage in rheumatoid arthritis and OA2, and increased 41 
levels of MMP-3 and stromelysin-2 (MMP-10) are found in articular cartilage and synovium 42 
of these patients.10, 27, 42 Gelatinase B (MMP-9) and collagenase-3 (MMP-13) coordinate 43 
cartilage collagen and aggrecan breakdown. Native collagen 2 is degraded by MMP-1, -8, -13, 44 
and -14, and partially degraded collagen 2 is then further degraded by MMP-2, MMP-9, and 45 
stromelysin-1 (MMP-3).4 46 
Another important cartilage component—and hence relevant in the context of 47 
cartilage mechanosensitivity—is type II collagen. In the process of collagen fibril formation, 48 
the C-propeptide is removed from the procollagen extracellularly and directly reflects the rate 49 
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of type II procollagen synthesis (CPII).24 Cleavage of type II collagen by collagenases yields 50 
fragments, such as the C2C epitope (COL2−3/4Clong mono)29, reflecting degradation. 51 
The purpose of this study was to determine serum changes in cartilage biomarkers 52 
during a multistage ultramarathon race. We hypothesized that serum concentrations of 53 
COMP, MMP-1, 3, and 9, C2C, CPII, and C2C:CPII will increase throughout a multistage 54 
ultramarathon. 55 
 56 
Materials and Methods 57 
Of the 67 participants of a 4486 km multistage ultramarathon from the South of Italy 58 
to the North Cape taking place from April 19 to June 2136, 36 runners (4 female; mean ± 1 59 
standard deviation; age, 49.0 ± 10.7 years; height, 174 ± 8 cm; body mass start, 70.2 ± 10.2 60 
kg, body mass finish, 65.2 ± 8.5 kg; body mass index, start: 23.1 ± 2.3 kg/m2, finish: 21.4 ± 61 
1.9 kg/m2) volunteered for this study after providing informed consent. This study was 62 
approved by the institutional review board and complied with the Declaration of Helsinki. 63 
The race comprised 64 running days without any rest days with a mean distance per stage of 64 
70.1 km (range, 44.0 to 95.1 km). All runners arrived at the same predetermined daily 65 
intermediate finish where they stayed overnight. Because of the season (late spring to early 66 
summer) and the route from South to North, temperatures stayed relatively constant 67 
throughout the race.36 All runners were official race participants meeting the ultramarathon 68 
registration requirements: ≥ 18 years; medical health certificate; and proof of appropriate 69 
ultramarathon running performance. In the 12 months prior to the race, participants spent an 70 
average 7 to 20 hours per week to run an average of 50 to 220 km per week. Five participants 71 
had a unilateral focal chondral defect in the patellofemoral joint (femur) and one participant 72 
in the tibiofemoral joint (tibia) without any symptoms diagnosed by magnetic resonance 73 
 7 
imaging MRI performed as part of an associated MRI study on these runners.35-37 The MR 74 
signal of these defects did not change throughout the ultramarathon.  75 
Serum samples were collected within 4 days prior to the race (t0) and on days 15 (t1: 76 
1002 km), 31 (t2: 2132 km), 47 (t3: 3234 km), and 58 (t4: 4039 km) of the 64-day race. 77 
Average running speed and daily running time for each of the four measurement intervals 78 
(MI; MI1: t1-t0; MI2: t2-t1; MI3: t3-t2; MI4: t4-t3) between blood sampling was calculated and 79 
body mass measured for each runner. Blood samples were taken from the cubital vein after 80 
the daily running stage. The samples were immediately centrifuged, aliquoted, frozen (below 81 
-20°C), and transferred to -80°C after the race. Serum biomarker levels were determined in 82 
duplicates using commercial enzyme-linked immunosorbent assays: (COMP: Wieslab® 83 
hCOMP quantitative kit (Euro Diagnostica AB, Malmö, Sweden); MMP-1: RayBio® Human 84 
MMP-1 ELISA kit (RayBiotech Inc., Norcross, GA, USA); MMP-3 and MMP-9: Human 85 
MMP-3 Quantikine Kit and Human MMP-9 Quantikine Kit (Bio-Techne Ltd., Abingdon, 86 
UK); C2C and CPII: Collagen Type II Cleavage Assay and Procollagen Type II C-Propeptide 87 
Assay (IBEX Technologies Inc. Montreal, Quebec, Canada)). All biomarkers were 88 
determined simultaneously for each sample upon thawing the sample to avoid refreezing 89 
samples. All samples of each participant were tested on the same plate to avoid any errors 90 
due to plate-to-plate differences. Intra-assay variability was assessed as relative coefficients 91 
of variation (CV%) between duplicates and was 4.8% for COMP, 3.7% for MMP-1, 7.0% for 92 
MMP-3, 2.7% for MMP-9, 6.9% for C2C, and 7.3% for CPII. 93 
 94 
Statistical analysis 95 
All statistical analyses were performed using SPSS Version 21 (IBM Corporation, 96 
Armonk, NY). All parameters were tested for normal distribution using Kolmogorow 97 
Smirnow tests. Linear mixed models were used to detect significant changes in serum 98 
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biomarker levels over time with time-varying covariates body mass, running speed, and daily 99 
running time, and posthoc least square tests. Because not all runners completed the entire race, 100 
missing data were handled by imputing values using the last observation carried forward 101 
method, and all models were rerun. Race finishing was used as between subject factor in the 102 
models (finisher versus non-finisher). The significance level for all statistical tests was set a 103 
priori to .05.  104 
 105 
Results 106 
Participants ran with an average running speed of 8.2 ± 1.4 km/h (mean ± 1 standard 107 
deviation) and lost an average of 5.3 ± 2.7 kg of body mass (Table 1). Six runners dropped 108 
out in MI2, one in MI3 and four in MI4. Age, height, body mass, running speed and 109 
biomarker levels after MI1 and MI2 did not differ between groups by time of dropout 110 
(P>.029). The following reasons for drop-out were reported: shin splint (N=4), thigh splint 111 
(N=2), foot pain with purulence (N=1), phlegmon finger treated by surgery (N=1), proximal 112 
tibia fracture (N=1), anterior pelvic ring fracture (N=1; participant with focal cartilage defect 113 
in patellofemoral joint), and respiratory infection (N=1). All other participants with focal 114 
cartilage defects completed the race. None of the biomarker results differed between 115 
Table 1. Mean (1 standard deviation) time varying covariates body mass, running speed and daily 
running time before and throughout the multistage ultramarathon. 
 
Parameter t0 
Pre-race 
(N=36) 
t1 
After 1002 km 
(N=36) 
t2 
After 2132 km 
(N=30) 
t3 
After 3234 km 
(N=29) 
t4 
After 4038 km 
(N=26) 
P-value  
finishera 
Body mass (kg) 70.6 
(9.9) 
67.6 
(9.2) 
66.4 
(8.8) 
65.6 
(8.8) 
65.2 
(8.5) 
<.001 
Mean running 
speed (km/h) 
 8.40 
(1.25) 
8.46 
(1.39) 
8.43 
(1.47) 
8.41 
(1.44) 
.955 
Mean daily 
running time (h) 
 8.1 
(1.1) 
7.7 
(1.3) 
7.9 
(1.2) 
7.8 
(1.6) 
.226 
a—results of the linear mixed models on the runners who completed the race (N=23). Note: The results of the 
linear mixed models did not change when data of non-finishers were considered using the last observation 
carried forward approach. 
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participants with or without focal cartilage defect.  116 
Serum concentrations of COMP, MMP-9 and MMP-3 changed significantly 117 
throughout the multistage ultramarathon (Table 2). On average, concentrations increased 118 
during MI1 by 22.5% (change MI1, COMP: [0.29;0.71] ng/mL), 22.3% (MMP-3: 119 
[0.24;15.37] ng/mL), and 95.6% (MMP-9: [81.7;414.5] ng/mL), and remained stable 120 
throughout MI2, MI3 and MI4 (Figure 1). Changes in serum COMP, MMP-3, and MMP-9 121 
concentrations during MI1 did not differ between finishers and non-finishers (time×finishing 122 
group interaction: P=.387, P=.620, and P=.945, respectively). Serum concentrations of MMP-123 
1, C2C, CPII, and C2C:CPII did not change significantly throughout the multistage 124 
ultramarathon (Table 2). The results of the linear mixed models did not change when data of 125 
non-finishers were considered using the last observation carried forward approach.  126 
The time varying covariate body mass was significantly associated with changes in 127 
COMP, MMP-3, and MMP-9 throughout the multistage ultramarathon (COMP: Wald 128 
Table 2. Mean (1 standard deviation) serum biomarker concentrations before and throughout the 
multistage ultramarathon. 
Cartilage 
biomarker 
t0 
Pre-race 
(N=36) 
t1 
After 1002 km 
(N=36) 
t2 
After 2132 km 
(N=30) 
t3 
After 3234 km 
(N=29) 
t4 
After 4038 km 
(N=23) 
P-value  
finishera 
COMP (ng/mL) 2.19 
(0.42) 
2.67 
(0.48) 
2.61 
(0.60) 
2.57 
(0.40) 
2.69 
(0.53) 
<.001 
MMP-1 (ng/mL) 20.07 
(25.06) 
20.88 
(30.28) 
26.32 
(23.21) 
33.93 
(30.08) 
32.04 
(23.42) 
0.328 
MMP-3 (ng/mL) 25.36 
(16.16) 
31.15 
(20.16) 
33.26 
(16.03) 
36.48 
(18.65) 
37.77 
(16.43) 
0.046 
MMP-9 (ng/mL) 232.71 
(207.83) 
444.11 
(453.74) 
484.47 
(295.11) 
568.10 
(311.10) 
541.52 
(262.67) 
<.001 
C2C (ng/mL) 166.45 
(48.77) 
185.92 
(60.76) 
175.63 
(47.24) 
154.24 
(44.83) 
162.17 
(29.31) 
.190 
CPII (µg/mL) 2.98 
(1.45) 
3.64 
(2.02) 
3.00 
(1.34) 
2.63 
(1.37) 
2.64 
(6.43) 
.067 
C2C:CPII 0.061 
(0.014) 
0.058 
(0.018) 
0.063 
(0.017) 
0.065 
(0.018) 
0.064 
(0.015) 
.407 
COMP—cartilage oligomeric matrix protein; MMP—matrix proteinases; C2C— C-terminal neoepitope generated 
by the collagenase-mediated cleavage of collagen type II triple helix; CPII— procollagen type II C-terminal 
propeptide; CPII—ratio of C2C and CPII reflecting collagen turnover. A—results of the linear mixed models on 
the runners who completed the race (N=23). Note: The results of the linear mixed models did not change when 
data of non-finishers were considered using the last observation carried forward approach. 
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Z=3.411, P=.002; MMP-3: Wald Z = 2.472, P=.013; MMP-9: Wald Z = 2.226, P=.026). The 129 
time varying covariates running speed and daily running time were not associated with 130 
changes in any cartilage biomarker. Changes in MMP-3 were associated with changes in 131 
COMP throughout the ultramarathon race (MMP-3: Wald Z=3.476, P=.001) where in 68% of 132 
runners ultramarathon-induced changes in MMP-3 levels explained more than 30% of 133 
ultramarathon-induced changes in COMP levels. Figure 2 shows an example of the 134 
relationship between MMP-3 and COMP levels for one participant. Changes in MMP-1, 135 
MMP-9, C2C, CPII or C2C:CPII were not associated with changes in COMP.  136 
 137 
Discussion 138 
The purpose of this study was to determine serum changes in cartilage biomarkers 139 
during a multistage ultramarathon race. COMP, MMP-3, and MMP-9 levels increased within 140 
the first 11 days of the ultra-marathon race and remained elevated throughout the remainder 141 
 
Figure 1. Mean relative changes in cartilage biomarkers normalized to baseline level. COMP—
cartilage oligomeric matrix protein; MMP—matrix proteinases; C2C— C-terminal neoepitope 
generated by the collagenase-mediated cleavage of collagen type II triple helix; CPII— 
procollagen type II C-terminal propeptide; C2C:CPII—ratio of C2C and CPII reflecting collagen 
turnover. 
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of the race. MMP-1, C2C and CPII levels and C2C:CPII did not change throughout the race. 142 
The time varying covariate body mass was associated with changes in COMP, MMP-3, and 143 
MMP-9 throughout the multistage ultramarathon. Changes in MMP-3 were associated with 144 
changes in COMP throughout the ultramarathon race. The results provide first evidence that 145 
only some cartilage biomarkers are sensitive to extreme running exercise and that changes in 146 
these biomarkers are correlated.  147 
Of the known potential cartilage biomarkers, COMP has been used most often as 148 
surrogate measure of cartilage degradation in studies on the effect of exercises of different 149 
intensities on articular cartilage. Interestingly, the magnitude of increase in COMP in our 150 
study (+22.5%) was not greater than that reported for marathon and single stage 151 
ultramarathon races. For instance, COMP levels did not change more than after other 152 
physical activities such as walking 14 km uphill30, walking for 30 minutes,21 walking 4000 153 
steps at slow, medium or fast walking speed,5 or running for 30 minutes.25 Moreover, 154 
increases in COMP after a marathon range from 17 to 60%.14, 22, 23 Kim et al. reported a 1.9- 155 
and 3-fold increase in COMP levels after 100 km and 200 km, respectively, of a 200 km 156 
single stage ultramarathon in two separate studies (mean race time, 32.5 hours).13, 14 In a 157 
single stage ultramarathon study by Shin et al.38, COMP levels increased by 130.7% at 100 158 
 
Figure 2. Relationship between MMP-3 and COMP levels for one participant. 
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km to 160.4% at 200 km and 194.1% at 308 km (mean race time, 61.5 hours). All of these 159 
studies have in common that COMP concentrations continued to increase throughout these 160 
single stage marathon14, 23 or single stage ultramarathon races.13, 14, 38 In contrast, serum 161 
COMP levels in our study remained stable throughout the multistage ultramarathon race after 162 
the initial 1002 km. Because the second blood draw was take 11 days into the race (after 163 
1002 km), information regarding a potential initial continuous increase or a peak in COMP 164 
level between days 1 and 11 of the race is not available. 165 
Previous studies have reported a recovery of COMP levels within 30 minutes to 166 
several days for light (30-minute walking21 or running25) and intense exercise (marathons14, 22, 167 
23 and ultramarathons14), respectively. Moreover, Mündermann et al.22 have shown that 168 
COMP levels in runners with faster marathon finishing times return to pre-race levels within 169 
24 hours of the marathon but not in those with slower marathon finishing times. The authors 170 
attributed these differences to different relative load between runners because of greater 171 
number of steps taken during the race in slower runners or differences in fitness among 172 
runners. In addition, a predefined walking exercise (4000 steps) at varying walking speeds 173 
(slow, medium, fast) resulted in systematic changes in COMP levels and these changes were 174 
related to differences in joint mechanics5. Accordingly, one could expect that changes in 175 
COMP during the multistage ultramarathon are associated with running speed and/or daily 176 
running time. However, the linear mixed models with time varying covariates did not reveal 177 
such an association in this group of experienced ultramarathon runners. Interestingly, a 3-178 
week multistage cycling race did not result in changes in COMP levels in pro-cyclists3. Like 179 
running, cycling is characterized by high cyclic joint loads (e.g. several times body weight at 180 
the knee15), but unlike in running, joint forces rise and fall without an impact peak caused by 181 
the collision of the body with the ground. The lack of changes in COMP levels in a 182 
multistage cycling race and increases in COMP levels in a multistage running race suggests 183 
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that COMP levels are sensitive to repetitive impact loads most likely of articular cartilage and 184 
not of other musculoskeletal tissues. 185 
The main differences between single stage and multistage ultramarathons are the 186 
much longer distances covered and the daily (usually overnight) resting times in multistage 187 
races. Based on COMP data from marathons and single stage ultramarathons, one would 188 
expect the magnitude of changes in COMP levels to increase with increasing distance with a 189 
gradual increase in levels throughout a race. The fact that COMP levels did not increase more 190 
during the multistage ultramarathon than reported increases in shorter single stage races 191 
suggests that the daily resting time may have been sufficient for tissue recovery to some 192 
extent. Slower runners took more time each day to complete the daily stage and hence had 193 
shorter overnight resting times implying less recovery. However, daily running time was not 194 
associated with changes in COMP. Hence, even in slower runners, overnight resting times 195 
may have been sufficient for preventing further increase in COMP levels throughout the race. 196 
It appears that cartilage reached a steady state during the race, which is further supported by 197 
previous reports35, 37 of an initial T2* increase in articular cartilage of the ankle and the knee 198 
followed by a subsequent T2* decrease (ankle)37 and steady-state (knee)35 in these runners. 199 
The changes in COMP levels reported here support the previous suggestion of the ability of 200 
the normal cartilage matrix at the ankle joints to partially regenerate with continuing 201 
multistage ultramarathon load.37 Participants of multistage ultramarathon races represent a 202 
unique sample of athletes that are extremely well conditioned because of extreme training 203 
regimens possibly explaining the smaller increases in COMP levels compared to those 204 
reported in marathon and single stage ultramarathon runners. These results are relevant not 205 
only for ultramarathon runners but also for elite athletes training for marathons requiring high 206 
weekly running distances or for extreme expeditions of several days or week. 207 
 14 
Cyclic loading enhances COMP expression in a fully developed pericellular matrix.9 208 
While some data on the effects of running on COMP are available, little is known on the 209 
effects of running on other cartilage biomarkers. COMP levels are a measure of intact COMP 210 
or COMP fragments in blood. However, it is unclear if these fragments are present because of 211 
simple turnover or cartilage breakdown. Hence, markers reflecting tissue metabolism must 212 
also be considered. MMP-3 and MMP-9 levels but not MMP-1, C2C, or CPII levels changed 213 
during the multistage ultramarathon. Interestingly, COMP, MMP-3, and MMP-9 but not 214 
MMP-1 levels changed during immobilization during a 21-day bed-rest study.16 Hence, 215 
COMP, MMP-3, and MMP-9 systematically respond to extreme load and to unloading 216 
emphasizing their importance in the mechanobiology of articular cartilage. MMP-3 is in part 217 
responsible for the degradation of non-collagen matrix proteins in cartilage in rheumatoid 218 
arthritis and OA2 and MMP-9 and MMP-13 coordinate cartilage collagen and aggrecan 219 
breakdown. The association of changes in MMP-3 levels with changes in COMP levels 220 
indicate that MMP-3 may be involved in the degradation of COMP. This result supports 221 
findings of in situ experiments where digestion of human articular cartilage with MMP-3, -12, 222 
or -13 but not with MMP-2, -8, or -9 yielded fragments of COMP.45 MMP-1 degrades 223 
collagen types I, II, and III in the extracellular matrix, and mediates cartilage destruction.2, 40 224 
The lack of changes in MMP-1, C2C and CPII levels, and in C2C:CPII suggest that the 225 
extreme running load did not affect collagen turnover. Similarly, COMP, MMP-3, and MMP-226 
9 but not MMP-1 levels changed in a 21-day bed rest study16, 17 suggesting that MMP-1 is not 227 
sensitive to loading. 228 
Henrotin et al.12 observed decreases in Coll2-1 levels (a denaturation epitope located 229 
in the triple helical domain of the type II collagen molecule that is made available by 230 
unwinding of the triple helix11) after a marathon, which they interpreted as a protective effect 231 
of long distance running on cartilage. In contrast, we did not observe changes in C2C or CPII 232 
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levels or in C2C:CPII during the multistage ultramarathon suggesting that the balance 233 
between collagen II synthesis and degradation was unaffected by the extreme running load. 234 
However, because the second sample was taken after about 1000 km, it is possible that we 235 
were unable to detect subtle changes early in the race. Moreover, it is possible that extreme 236 
load does not initiate collagen turnover but causes reorganization or loss of organization of 237 
the matrix and degradation of proteoglycans resulting in an increases in glucosaminoglycan 238 
content31, 32, which has also been indicated by previously observed changes in T2* of 239 
articular cartilage at the ankle during a multistage ultramarathon.37  240 
Some discrepancies between our results and the literature may have been caused by 241 
methodological differences. For instance, while many studies used a blood sample taken 242 
within 2 hours prior to the race as baseline value, in other studies baseline samples were 243 
taken 24 hours before the marathon41, 6 to 10 hours before the ultramarathon14, and up to 4 244 
days before the multistage marathon in our study. Moreover, none of the studies specified 245 
whether physical activity prior to the baseline sample was controlled or restricted which may 246 
influence baseline levels.21 Interestingly, most studies13, 14, 22, 38 on marathon and 247 
ultramarathon running involve participants with an average age around 50 years who were 248 
experienced ultramarathon runners when 25% of the population between 45 and 64 years 249 
suffer from arthritis or joint pain.1 Some runners had focal lesion in the patellofemoral joint 250 
without any symptoms, and the MR signal did not change throughout the race. Hence, the 251 
patellofemoral joint may not have been adversely affected by the extreme running exercise on 252 
flat ground. Further, it is possible that only athletes without any joint degeneration affecting 253 
joint mechanics will participate in such a physically and mentally demanding sports. Based 254 
on the literature it is also feasible that a stringent training regimen over a long time may 255 
protect against cartilage degeneration in the tibiofemoral and ankle joints as previously 256 
shown in animal studies8, 28 and suggested by Schütz et al.37 257 
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 258 
Conclusions 259 
The results of this study provide evidence that physical load affects some cartilage 260 
biomarkers (COMP, MMP-9, and MMP-3 but not MMP-1, C2C, CPII, or C2C:CPII) and that 261 
the magnitude of these changes appear to be limited by providing regular short recovery 262 
periods throughout ultra-running exercises in highly adapted ultra-endurance athletes. While 263 
COMP levels may play an important role in the mechanotransduction of ambulatory load to 264 
chondrocytes, the role of COMP concentration on cartilage health in this population remains 265 
unclear. Nonetheless, elevated COMP levels indicate increased COMP turnover in response 266 
to extreme running, and the association between load-induced changes in MMP-3 and 267 
changes in COMP suggests the possibility that MMP-3 may be involved in the degradation of 268 
COMP. The lack of changes in MMP-1, C2C, CPII, and C2C:CPII indicate that these 269 
markers are not involved in load-induced changes in articular cartilage. 270 
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